False-Positive Results in a Recombinant Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Nucleocapsid Enzyme-Linked Immunosorbent Assay Due to HCoV-OC43 and HCoV-229E Rectified by Western Blotting with Recombinant SARS-CoV Spike Polypeptide

ABSTRACT Using paired serum samples obtained from patients with illness associated with increases in anti-human coronavirus OC43 (HCoV-OC43) or anti-HCoV-229E antibodies, we examined the possibility of false-positive results detected in a recombinant severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein immunoglobulin G enzyme-linked immunosorbent assay (ELISA). Three of the 21 and 1 of the 7 convalescent-phase serum samples from persons with increases in antibodies against HCoV-OC43 and HCoV-229E, respectively, tested positive by the recombinant SARS-CoV nucleocapsid protein-based ELISA. None of these samples were found to contain a specific antibody in the recombinant SARS-CoV spike polypeptide-based Western blot assay.

[1]  R. Couch,et al.  Development and application of an enzyme immunoassay for coronavirus OC43 antibody in acute respiratory illness , 1994, Journal of clinical microbiology.

[2]  K. Yuen,et al.  Characterization of AFMP1: a Novel Target for Serodiagnosis of Aspergillosis , 2001, Journal of Clinical Microbiology.

[3]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[4]  K. Yuen,et al.  Detection of Antibodies Specific to an Antigenic Cell Wall Galactomannoprotein for Serodiagnosis of Aspergillus fumigatus Aspergillosis , 2002, Journal of Clinical Microbiology.

[5]  Xinchun Chen,et al.  Serology of Severe Acute Respiratory Syndrome: Implications for Surveillance and Outcome , 2004, The Journal of infectious diseases.

[6]  P. Woo,et al.  Detection of Specific Antibodies to Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein for Serodiagnosis of SARS Coronavirus Pneumonia , 2004, Journal of Clinical Microbiology.

[7]  T. Cate,et al.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement , 1980, Journal of clinical microbiology.

[8]  Yuh‐Cheng Yang,et al.  Antibody detection of SARS-CoV spike and nucleocapsid protein , 2004, Biochemical and Biophysical Research Communications.

[9]  Yi Guan,et al.  Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia , 2004, The Lancet.

[10]  Huanming Yang,et al.  Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2003, Clinical chemistry.

[11]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[12]  S. Kliche,et al.  Enzyme-linked immunosorbent assay for detecting antibodies to Borna disease virus-specific proteins , 1995, Journal of clinical microbiology.

[13]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[14]  Y. Leo,et al.  Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers , 2004, Clinical Diagnostic Laboratory Immunology.

[15]  K. Yuen,et al.  AFLMP1 Encodes an Antigenic Cell Wall Protein in Aspergillus flavus , 2003, Journal of Clinical Microbiology.

[16]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[17]  A. H. Wang,et al.  Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients , 2004, Journal of Biomedical Science.

[18]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.